Physician profile
Michael Flicker
NPI 1730375627
$15,733.28
in general payments reported to CMS, 2019-2025
35 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,629 · 2020: $3,331 · 2021: $2,983 · 2022: $738 · 2023: $1,123 · 2024: $672 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177 · Consulting Fee: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.28 |
| Consulting Fee | $875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,301.13 | 2019-2020 | |
| Abbvie INC. | $3,653.01 | 2019-2025 | |
| Boston Scientific Corporation | $1,448.83 | 2019-2025 | Orcapod, Resolution 360 Ultra Clip, Exalt Model D |
| Olympus Medical Systems Corporation | $875.00 | 2025 | Evis Exera III Duodenovideoscope |
| Janssen Biotech, INC. | $845.68 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.87 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $442.22 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $385.06 | 2019-2025 | |
| Pfizer INC. | $354.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $242.28 | 2021-2022 | |
| Cook Medical LLC | $206.70 | 2019-2023 | Hemospray |
| Ardelyx, INC. | $176.41 | 2024-2025 | Ibsrela |
| Covidien Lp | $173.07 | 2019-2020 | |
| Qol Medical, LLC | $146.64 | 2022 | |
| Conmed Corporation | $125.00 | 2023 | Conmed Biliary |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $96.44 | 2020 | |
| Merck Sharp & Dohme LLC | $84.59 | 2020-2024 | Dificid |
| Madrigal Pharmaceuticals | $72.96 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $72.76 | 2020-2022 | |
| Celgene Corporation | $72.57 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $61.47 | 2024-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $46.04 | 2023 | |
| Phathom Pharmaceuticals, INC. | $45.50 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $38.97 | 2025 | Iqirvo |
| Ucb, INC. | $36.96 | 2019 | |
| Genzyme Corporation | $29.89 | 2025 | |
| Intercept Pharmaceuticals, INC. | $25.97 | 2020 | |
| Lilly USA, LLC | $25.03 | 2025 | Omvoh |
| Amag Pharmaceuticals, INC. | $21.95 | 2021 | |
| Redhill Biopharma INC. | $20.04 | 2021 | |
| Aimmune Therapeutics, INC. | $18.14 | 2024 | |
| Vivus LLC | $16.93 | 2024 | Qsymia |
| Echosens North America, INC. | $14.21 | 2024 | Fibroscan |
| Ferring Pharmaceuticals INC. | $13.67 | 2020 | |
| Ethicon US, LLC | $13.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.